Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab, Bevacizumab, and Tafolecimab in Advanced NSCLC Post-PD-1/L1
NCT07014215Phase 2Not yet recruiting
- Sponsor
- Anhui Provincial Tumor Hospital
- Start
- Jun 2025
- Primary completion
- May 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 2 trial of tafolecimab in non-small cell lung cancer (NSCLC), sponsored by Anhui Provincial Tumor Hospital. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
tafolecimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07014215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014215.